Boston Scientific determined to gain ground in medical device sales in emerging markets
If emerging-market revenue were a horse race, Boston Scientific would be bringing up the rear. But the medical device maker is fervently determined to gain ground, with stepped-up efforts to sell pacemakers, defibrillators and other technology overseas.
"We're making great strides to narrow that gap, and we're developing capabilities more fully in emerging markets," said Boston Scientific President and CEO Mike Mahoney. "Our emerging-market sales increased to 9 percent of our total company operating sales in fourth quarter 2013, and we anticipate emerging-market sales will grow to an estimated 15